Business
Aurora Spine Corporation Announces First Quarter FY26 Financial Results
- Company to host conference call Today, May 28th at 10am ET/7am PT –NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical devices for spinal surgery, today announced its financial results for the first quarter of fiscal year 2026 ended March 31, 2026. All figures are in U.S. dollars
About this update from Aurora Spine Corp.
[{"type":"image","alt":"Aurora Spine Corporation","displaySize":"","headline":null,"caption":"Aurora Spine Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":90,"url":"https://media.zenfs.com/en/globenewswire.com/09dc0294555d94a4861b2d105c0484d1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/T3EJY5080dWSmJr07jHsIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNg--/https://media.zenfs.com/en/globenewswire.com/09dc0294555d94a4861b2d105c0484d1","width":300,"height":90},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/T3EJY5080dWSmJr07jHsIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNg--/https://media.zenfs.com/en/globenewswire.com/09dc0294555d94a4861b2d105c0484d1","width":300,"height":90}},"lazy":false},{"type":"text","content":"- Company to host conference call Today, May 28th at 10am ET/7am PT –","length":80,"tagName":"p"},{"type":"text","content":"NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES","length":77,"tagName":"p"},{"type":"text","content":"CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical devices for spinal surgery, today announced its financial results for the first quarter of fiscal year 2026 ended March 31, 2026.","length":321,"tagName":"p"},{"type":"text","content":"All figures are in U.S. dollars.","length":32,"tagName":"p"},{"type":"text","content":"Financial and Business Highlights","length":33,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Increased gross profit margin – Gross profit margin on total revenues was 62.6% for Q1 of 2026, compared to 58.0% in Q1 of 2025, due to improved product mix and direct sales initiatives.","length":186,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":186,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Improvement in EBITDAC – EBITDAC for Q1 was $106,765 compared to $(20,924) in Q1 2025, an improvement of $127,689.","length":114,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":114,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Increased sales of biologics – Successfully launched Aurora Biologics in late 2025 which contributed to a 124% increase in sales in Q1 compared to last yea...